Oncolytic virus and immunotherapy for recurrent high-grade glioma
Part of Cancer clinical trials.
This trial tests a new treatment combining an oncolytic virus with a PD-1 inhibitor for people whose high-grade glioma has come back after standard therapy. The virus is injected directly into the tumor through a device placed in the head, and the drug helps your immune system fight the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade glioma that has returned after standard treatment.
- You are at least 18 years old.
- You have a tumor that is at least 1 cm in size on an MRI scan.
- You are healthy enough for surgery to place a small device in your head to deliver the virus into the tumor.
- Your kidney, liver, and blood counts are within certain safe limits.
- You have not had cell therapy, gene therapy, or oncolytic virus treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
This trial tests a combination of two immunotherapy drugs (relatlimab and nivolumab) for newly diagnosed high-grade gliomas and brainstem tumors that have specific genetic mutations. The goal is to see if this treatment approach can help your immune system fight the cancer.
This trial tests a modified virus that may help treat a type of brain cancer called high-grade glioma. It is for patients who have not yet had any treatment for their tumor.
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
This Phase 1 trial tests a lab-made cancer virus (Ad-TD-nsIL12) in children with DIPG whose tumor keeps growing after standard treatment. It mainly focuses on safety and how the treatment works, and it may help shrink or control the tumor by stimulating the immune system.
This trial tests a vaccine made from your own immune cells (dendritic cells) to see if it can help control recurrent or progressive high-grade gliomas. It is for people whose brain tumor has returned after standard treatments.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.